Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers - PubMed (original) (raw)
Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
A H Jan Danser et al. Hypertension. 2020 Jun.
Abstract
During the spread of the severe acute respiratory syndrome coronavirus-2, some reports of data still emerging and in need of full analysis indicate that certain groups of patients are at risk of COVID-19. This includes patients with hypertension, heart disease, diabetes mellitus, and clearly the elderly. Many of those patients are treated with renin-angiotensin system blockers. Because the ACE2 (angiotensin-converting enzyme 2) protein is the receptor that facilitates coronavirus entry into cells, the notion has been popularized that treatment with renin-angiotensin system blockers might increase the risk of developing a severe and fatal severe acute respiratory syndrome coronavirus-2 infection. The present article discusses this concept. ACE2 in its full-length form is a membrane-bound enzyme, whereas its shorter (soluble) form circulates in blood at very low levels. As a mono-carboxypeptidase, ACE2 contributes to the degradation of several substrates including angiotensins I and II. ACE (angiotensin-converting enzyme) inhibitors do not inhibit ACE2 because ACE and ACE2 are different enzymes. Although angiotensin II type 1 receptor blockers have been shown to upregulate ACE2 in experimental animals, the evidence is not always consistent and differs among the diverse angiotensin II type 1 receptor blockers and differing organs. Moreover, there are no data to support the notion that ACE inhibitor or angiotensin II type 1 receptor blocker administration facilitates coronavirus entry by increasing ACE2 expression in either animals or humans. Indeed, animal data support elevated ACE2 expression as conferring potential protective pulmonary and cardiovascular effects. In summary, based on the currently available evidence, treatment with renin-angiotensin system blockers should not be discontinued because of concerns with coronavirus infection.
Keywords: ACE inhibitor; COVID-19; angiotensin receptor blocker; coronavirus; severe acute respiratory syndrome.
Figures
Figure.
Overview of the connections between renin-angiotensin system blockers, ACE2 (angiotensin-converting enzyme 2) and the coronavirus. The carboxypeptidase ACE2 converts Ang II (angiotensin II) to Ang-(1–7) and Ang I to Ang-(1–9) (A), yet is not blocked by ACE (angiotensin-converting enzyme) inhibitors, which prevent the conversion of Ang I to Ang II. ACE2 also binds and internalizes SARS-Cov-2 (severe acute respiratory syndrome coronavirus-2; B), after priming by the serine protease TMPRSS2 (transmembrane protease, serine 2). Shedding of membrane-bound ACE2 by a disintegrin and metalloprotease 17 (ADAM17) results in the occurrence of soluble (s) ACE2, which can no longer mediate SARS-Cov-2 entry and which might even prevent such entry by keeping the virus in solution. AT1R (Ang II, via its type 1 receptor) upregulates ADAM17, and AT1R blockers (ARBs) would prevent this.
Comment in
- Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality.
Zhou F, Liu YM, Xie J, Li H, Lei F, Yang H, Qin JJ, Cai J, Zhang XJ, Wu B, Xia M, Xiang D, Yang C, Ma X, Xu Q, Lu Z, Lu H, Xia X, Wang D, Liao X, Peng G, Yang J, Huang X, Zhang BH, Yuan Y, Wei X, Liu PP, Wang Y, Zhang P, She ZG, Xia J, Li H. Zhou F, et al. Hypertension. 2020 Aug;76(2):e15-e17. doi: 10.1161/HYPERTENSIONAHA.120.15622. Epub 2020 Jun 3. Hypertension. 2020. PMID: 32493070 No abstract available.
Similar articles
- Drugs acting on renin angiotensin system and use in ill patients with COVID-19.
Alexandre J, Cracowski JL, Richard V, Bouhanick B; French Society of Pharmacology and Therapeutics (SFPT). Alexandre J, et al. Therapie. 2020 Jul-Aug;75(4):319-325. doi: 10.1016/j.therap.2020.05.009. Epub 2020 May 20. Therapie. 2020. PMID: 32553503 Free PMC article. Review. - Renin-angiotensin-aldosterone system and COVID-19 infection.
Alexandre J, Cracowski JL, Richard V, Bouhanick B; 'Drugs, COVID-19' working group of the French Society of Pharmacology, Therapeutics. Alexandre J, et al. Ann Endocrinol (Paris). 2020 Jun;81(2-3):63-67. doi: 10.1016/j.ando.2020.04.005. Epub 2020 Apr 21. Ann Endocrinol (Paris). 2020. PMID: 32370986 Free PMC article. Review. - [Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers].
Kreutz R, Abd El-Hady Algharably E, Ganten D, Messerli F. Kreutz R, et al. Pneumologie. 2020 Sep;74(9):611-614. doi: 10.1055/a-1165-6994. Epub 2020 Sep 11. Pneumologie. 2020. PMID: 32916743 German. No abstract available. - [Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers].
Kreutz R, Abd El-Hady Algharably E, Ganten D, Messerli F. Kreutz R, et al. Dtsch Med Wochenschr. 2020 May;145(10):682-686. doi: 10.1055/a-1152-3469. Epub 2020 Apr 22. Dtsch Med Wochenschr. 2020. PMID: 32323279 Free PMC article. Review. German. - Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2.
Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, Raizada MK, Grant MB, Oudit GY. Gheblawi M, et al. Circ Res. 2020 May 8;126(10):1456-1474. doi: 10.1161/CIRCRESAHA.120.317015. Epub 2020 Apr 8. Circ Res. 2020. PMID: 32264791 Free PMC article. Review.
Cited by
- [Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry].
López-Otero D, López-Pais J, Cacho-Antonio CE, Antúnez-Muiños PJ, González-Ferrero T, Pérez-Poza M, Otero-García Ó, Díaz-Fernández B, Bastos-Fernández M, Bouzas-Cruz N, Sanmartín-Pena XC, Varela-Román A, Portela-Romero M, Valdés-Cuadrado L, Pose-Reino A, González-Juanatey JR. López-Otero D, et al. Rev Esp Cardiol. 2021 Feb;74(2):175-182. doi: 10.1016/j.recesp.2020.05.030. Epub 2020 Jul 19. Rev Esp Cardiol. 2021. PMID: 32836666 Free PMC article. Spanish. - Drugs acting on renin angiotensin system and use in ill patients with COVID-19.
Alexandre J, Cracowski JL, Richard V, Bouhanick B; French Society of Pharmacology and Therapeutics (SFPT). Alexandre J, et al. Therapie. 2020 Jul-Aug;75(4):319-325. doi: 10.1016/j.therap.2020.05.009. Epub 2020 May 20. Therapie. 2020. PMID: 32553503 Free PMC article. Review. - Effect of angiotensin II blockers on the prognosis of COVID-19: a toxicological view.
Shirazi FM, Banerji S, Nakhaee S, Mehrpour O. Shirazi FM, et al. Eur J Clin Microbiol Infect Dis. 2020 Oct;39(10):2001-2002. doi: 10.1007/s10096-020-03932-6. Epub 2020 Jun 16. Eur J Clin Microbiol Infect Dis. 2020. PMID: 32557325 Free PMC article. No abstract available. - Multifactorial Traits of SARS-CoV-2 Cell Entry Related to Diverse Host Proteases and Proteins.
You J, Seok JH, Joo M, Bae JY, Kim JI, Park MS, Kim K. You J, et al. Biomol Ther (Seoul). 2021 May 1;29(3):249-262. doi: 10.4062/biomolther.2021.048. Biomol Ther (Seoul). 2021. PMID: 33875625 Free PMC article. Review. - A call to action becomes practice: cardiac and vascular surgery during the COVID-19 pandemic based on the Lombardy emergency guidelines.
Bonalumi G, Giambuzzi I, Barbone A, Ranieri C, Cavallotti L, Trabattoni P, Naliato M, Polvani G, Torracca L, Pelenghi S, Ragni F, Russo CF, Guerra F, Trimarchi S, Civilini E, Romani F, Bellosta R, Losa S, Roberto M, Alamanni F. Bonalumi G, et al. Eur J Cardiothorac Surg. 2020 Aug 1;58(2):319-327. doi: 10.1093/ejcts/ezaa204. Eur J Cardiothorac Surg. 2020. PMID: 32584978 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous